Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia

Rolf Muschter, Jean J M C H De La Rosette, Hugh Whitfield, Jean Pierre Pellerin, Stephan Madersbacher, David Gillatt

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objectives. To report the initial results of treatment of outlet obstruction induced by benign prostatic hyperplasia (BPH) using interstitial laser coagulation performed with the Indigo 830 nm diode laser system. Methods. A group of 112 men with lower urinary tract symptoms caused by BPH underwent treatment with the indigo 830 nm laser system between October 1994 and November 1995. Patients were assessed prior to treatment and at specified post-treatment intervals for symptom score, uroflow, postvoid residual, and prostate volume. Adverse events and changes in laboratory parameters were monitored at each post-treatment visit to investigate safety of the procedure. Results. Symptom score decreased from 20.9 at initial measurement to 9.6 at 3 months after procedure and 7.9 at 6 months. Uroflow rate increased from 8.0 mL/s initially to 15.2 and 14.2 mL/s at 3 and 6 months, respectively. Residual bladder volumes decreased from 105 mL initially to 59 and 38 mL at 3 and 6 months, respectively. There were no major complications (impotence, sustained incontinence, significant blood loss). Minor complications occurred in a small number of patients but were generally associated with urinary tract infection in patients with catheters. Three patients (2.7%) required retreatment and underwent transurethral resection of the prostate. Conclusions. Interstitial laser coagulation using an 830-nm diode laser system appears to be a promising new treatment, with substantial improvements in objective and subjective parameters of obstruction and a favorable side-effect profile.

LanguageEnglish
Pages223-228
Number of pages6
JournalUrology
Volume48
Issue number2
DOIs
Publication statusPublished - Aug 1996

Fingerprint

Semiconductor Lasers
Prostatic Hyperplasia
Indigo Carmine
Laser Coagulation
Residual Volume
Therapeutics
Lower Urinary Tract Symptoms
Transurethral Resection of Prostate
Retreatment
Erectile Dysfunction
Urinary Tract Infections
Prostate
Urinary Bladder
Lasers
Catheters
Safety

Cite this

Muschter, R., De La Rosette, J. J. M. C. H., Whitfield, H., Pellerin, J. P., Madersbacher, S., & Gillatt, D. (1996). Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia. Urology, 48(2), 223-228. https://doi.org/10.1016/S0090-4295(96)00156-2
Muschter, Rolf ; De La Rosette, Jean J M C H ; Whitfield, Hugh ; Pellerin, Jean Pierre ; Madersbacher, Stephan ; Gillatt, David. / Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia. In: Urology. 1996 ; Vol. 48, No. 2. pp. 223-228.
@article{33b16880ee2241deb08c310f67f07f1b,
title = "Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia",
abstract = "Objectives. To report the initial results of treatment of outlet obstruction induced by benign prostatic hyperplasia (BPH) using interstitial laser coagulation performed with the Indigo 830 nm diode laser system. Methods. A group of 112 men with lower urinary tract symptoms caused by BPH underwent treatment with the indigo 830 nm laser system between October 1994 and November 1995. Patients were assessed prior to treatment and at specified post-treatment intervals for symptom score, uroflow, postvoid residual, and prostate volume. Adverse events and changes in laboratory parameters were monitored at each post-treatment visit to investigate safety of the procedure. Results. Symptom score decreased from 20.9 at initial measurement to 9.6 at 3 months after procedure and 7.9 at 6 months. Uroflow rate increased from 8.0 mL/s initially to 15.2 and 14.2 mL/s at 3 and 6 months, respectively. Residual bladder volumes decreased from 105 mL initially to 59 and 38 mL at 3 and 6 months, respectively. There were no major complications (impotence, sustained incontinence, significant blood loss). Minor complications occurred in a small number of patients but were generally associated with urinary tract infection in patients with catheters. Three patients (2.7{\%}) required retreatment and underwent transurethral resection of the prostate. Conclusions. Interstitial laser coagulation using an 830-nm diode laser system appears to be a promising new treatment, with substantial improvements in objective and subjective parameters of obstruction and a favorable side-effect profile.",
author = "Rolf Muschter and {De La Rosette}, {Jean J M C H} and Hugh Whitfield and Pellerin, {Jean Pierre} and Stephan Madersbacher and David Gillatt",
year = "1996",
month = "8",
doi = "10.1016/S0090-4295(96)00156-2",
language = "English",
volume = "48",
pages = "223--228",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier",
number = "2",

}

Muschter, R, De La Rosette, JJMCH, Whitfield, H, Pellerin, JP, Madersbacher, S & Gillatt, D 1996, 'Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia', Urology, vol. 48, no. 2, pp. 223-228. https://doi.org/10.1016/S0090-4295(96)00156-2

Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia. / Muschter, Rolf; De La Rosette, Jean J M C H; Whitfield, Hugh; Pellerin, Jean Pierre; Madersbacher, Stephan; Gillatt, David.

In: Urology, Vol. 48, No. 2, 08.1996, p. 223-228.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia

AU - Muschter, Rolf

AU - De La Rosette, Jean J M C H

AU - Whitfield, Hugh

AU - Pellerin, Jean Pierre

AU - Madersbacher, Stephan

AU - Gillatt, David

PY - 1996/8

Y1 - 1996/8

N2 - Objectives. To report the initial results of treatment of outlet obstruction induced by benign prostatic hyperplasia (BPH) using interstitial laser coagulation performed with the Indigo 830 nm diode laser system. Methods. A group of 112 men with lower urinary tract symptoms caused by BPH underwent treatment with the indigo 830 nm laser system between October 1994 and November 1995. Patients were assessed prior to treatment and at specified post-treatment intervals for symptom score, uroflow, postvoid residual, and prostate volume. Adverse events and changes in laboratory parameters were monitored at each post-treatment visit to investigate safety of the procedure. Results. Symptom score decreased from 20.9 at initial measurement to 9.6 at 3 months after procedure and 7.9 at 6 months. Uroflow rate increased from 8.0 mL/s initially to 15.2 and 14.2 mL/s at 3 and 6 months, respectively. Residual bladder volumes decreased from 105 mL initially to 59 and 38 mL at 3 and 6 months, respectively. There were no major complications (impotence, sustained incontinence, significant blood loss). Minor complications occurred in a small number of patients but were generally associated with urinary tract infection in patients with catheters. Three patients (2.7%) required retreatment and underwent transurethral resection of the prostate. Conclusions. Interstitial laser coagulation using an 830-nm diode laser system appears to be a promising new treatment, with substantial improvements in objective and subjective parameters of obstruction and a favorable side-effect profile.

AB - Objectives. To report the initial results of treatment of outlet obstruction induced by benign prostatic hyperplasia (BPH) using interstitial laser coagulation performed with the Indigo 830 nm diode laser system. Methods. A group of 112 men with lower urinary tract symptoms caused by BPH underwent treatment with the indigo 830 nm laser system between October 1994 and November 1995. Patients were assessed prior to treatment and at specified post-treatment intervals for symptom score, uroflow, postvoid residual, and prostate volume. Adverse events and changes in laboratory parameters were monitored at each post-treatment visit to investigate safety of the procedure. Results. Symptom score decreased from 20.9 at initial measurement to 9.6 at 3 months after procedure and 7.9 at 6 months. Uroflow rate increased from 8.0 mL/s initially to 15.2 and 14.2 mL/s at 3 and 6 months, respectively. Residual bladder volumes decreased from 105 mL initially to 59 and 38 mL at 3 and 6 months, respectively. There were no major complications (impotence, sustained incontinence, significant blood loss). Minor complications occurred in a small number of patients but were generally associated with urinary tract infection in patients with catheters. Three patients (2.7%) required retreatment and underwent transurethral resection of the prostate. Conclusions. Interstitial laser coagulation using an 830-nm diode laser system appears to be a promising new treatment, with substantial improvements in objective and subjective parameters of obstruction and a favorable side-effect profile.

UR - http://www.scopus.com/inward/record.url?scp=0030217933&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00156-2

DO - 10.1016/S0090-4295(96)00156-2

M3 - Article

VL - 48

SP - 223

EP - 228

JO - Urology

T2 - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -